Free Trial

PTC Therapeutics (PTCT) Competitors

PTC Therapeutics logo
$48.74 +1.09 (+2.29%)
Closing price 04:00 PM Eastern
Extended Trading
$48.78 +0.04 (+0.09%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTCT vs. ITCI, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, and VRNA

Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

PTC Therapeutics vs. Its Competitors

Intra-Cellular Therapies (NASDAQ:ITCI) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

PTC Therapeutics has a net margin of 33.56% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intra-Cellular Therapies-14.07% -9.93% -8.38%
PTC Therapeutics 33.56%-78.56%32.11%

Intra-Cellular Therapies has higher earnings, but lower revenue than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64
PTC Therapeutics$806.78M4.79-$363.30M$6.517.49

92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. PTC Therapeutics has a consensus price target of $65.00, indicating a potential upside of 33.36%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
PTC Therapeutics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67

Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

In the previous week, PTC Therapeutics had 7 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 8 mentions for PTC Therapeutics and 1 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.00 beat PTC Therapeutics' score of -0.31 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intra-Cellular Therapies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PTC Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

PTC Therapeutics beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTCT vs. The Competition

MetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.78B$2.90B$5.51B$8.96B
Dividend YieldN/A2.44%5.25%4.02%
P/E Ratio7.4921.0128.0520.16
Price / Sales4.79295.02438.35127.91
Price / CashN/A41.8337.0657.97
Price / Book-3.427.868.125.62
Net Income-$363.30M-$54.95M$3.16B$248.50M
7 Day Performance-0.83%6.24%4.40%5.54%
1 Month Performance-5.71%5.70%4.09%7.52%
1 Year Performance54.48%8.08%34.53%22.06%

PTC Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTCT
PTC Therapeutics
4.2874 of 5 stars
$48.74
+2.3%
$65.00
+33.4%
+50.2%$3.78B$806.78M7.491,410
ITCI
Intra-Cellular Therapies
0.7269 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560News Coverage
GMAB
Genmab A/S
4.0603 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-16.6%$13.25B$3.12B11.742,682News Coverage
Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7856 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-4.7%$12.55B$3.81B22.7727,811
QGEN
Qiagen
3.8788 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+22.3%$10.69B$1.98B120.525,765
MRNA
Moderna
4.4616 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-72.1%$10.67B$3.24B-3.165,800
ASND
Ascendis Pharma A/S
3.4929 of 5 stars
$172.60
+0.2%
$220.67
+27.8%
+23.2%$10.55B$393.54M-27.481,017
VTRS
Viatris
3.3379 of 5 stars
$8.93
-0.9%
$10.40
+16.5%
-12.7%$10.48B$14.74B-2.8232,000
BPMC
Blueprint Medicines
1.5416 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+10.4%$8.28B$562.12M-51.89640News Coverage
Insider Trade
BBIO
BridgeBio Pharma
4.6844 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+65.2%$8.20B$221.90M-12.23400Analyst Upgrade
Gap Up
High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
1.7442 of 5 stars
$94.58
+0.8%
$101.10
+6.9%
+410.6%$8.05B$42.28M-47.2930Trending News
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:PTCT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners